Compare ATAI & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATAI | SVRA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | N/A |
| Metric | ATAI | SVRA |
|---|---|---|
| Price | $3.98 | $5.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $13.86 | $7.33 |
| AVG Volume (30 Days) | ★ 3.8M | 1.4M |
| Earning Date | 03-16-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,018,000.00 | N/A |
| Revenue This Year | $956.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | N/A |
| 52 Week Low | $1.15 | $1.89 |
| 52 Week High | $6.75 | $7.01 |
| Indicator | ATAI | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 40.57 |
| Support Level | $3.32 | $5.10 |
| Resistance Level | $4.01 | $5.44 |
| Average True Range (ATR) | 0.24 | 0.32 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 75.89 | 12.73 |
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.